Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs